NewLink Genetics Corporation Reports Fourth Quarter and Year End 2013 Financial Results
NewLink reported a net loss of
Research and development expense in the fourth quarter of 2013 was
General and administrative expense in the fourth quarter of 2013 was
NewLink ended the year on
Algenpantucel-L. Completed the first interim analysis in the Phase 3 IMPRESS clinical study of algenpantucel-L for patients with surgically resected pancreatic cancer. As part of the planned interim analysis, scheduled to occur following 222 patient events, the independent data safety monitoring committee (DSMC) met to review available patient data. Following their review, the DSMC recommended that the study should proceed as planned, without modification. A second interim analysis is planned upon reaching 333 patient events and, if needed, a final analysis is planned at 444 patient events.
HyperAcute Renal. Launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer. HyperAcute Renal, NewLink's most recent HyperAcute immunotherapy product candidate, is a novel biologic designed to stimulate the patient's immune system to recognize and attack cancer cells. This platform includes algenpantucel-L, NewLink's most advanced HyperAcute immunotherapy, which is currently in Phase 3 clinical development for the treatment of pancreatic cancer, tergenpumatucel-L for the treatment of non-small cell lung cancer, dorgenmeltucel-L for the treatment of melanoma and HyperAcute Prostate for the treatment of prostate cancer.
NLG919. Initiated a first in human Phase 1 clinical trial of NLG919in patients with recurrent advanced solid tumors. NLG919, NewLink's second IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, is a small-molecule, orally bioavailable, checkpoint inhibitor designed to counteract a fundamental mechanism by which tumors evade immune-mediated destruction. NLG919represents a novel class of compounds from NewLink's IDO pathway platform. This platform includes indoximod, NewLink's most advanced IDO pathway inhibitor, which is currently in Phase 2 clinical development for the treatment of breast cancer.
Key 2014 Milestones
HyperAcute Platform. We will continue to enroll patients in ongoing studies with algenpantucel-L in our Phase 3 study in locally advanced pancreatic cancer, with tergenpumatucel-L in our Phase 2b/3 study in advanced NSCLC and our Phase 1 study in metastatic renal cancer with our new HyperAcute renal product candidate. We also plan to advance dorgenmeltucel-L, our HyperAcute melanoma product candidate into a Phase 1b/2 combination immunotherapy trial for advanced melanoma and to initiate a Phase 1b/2 study evaluating a combination of one of our HyperAcute product candidates with one of our IDO pathway inhibitor candidates.
IDO Pathway Inhibitor Platform. We will continue to enroll patients in our ongoing Phase 2 studies combining indoximod with docetaxel in advanced breast cancer and with sipuleucel-T in metastatic castration resistant prostate cancer and in our Phase 1b/2 study combining indoximod with temozolomide in advanced brain tumors. Beyond this, we plan to initiate a Phase 1b/2 study in advanced melanoma combining indoximod and ipilimumab as well as a Phase 1b/2 study in metastatic pancreatic cancer combining indoximod with gemcitabine and nab-paclitaxel. We expect to evaluate the synergy between our two IDO pathway inhibitors and upon completion of Phase 1 to advance
NLG 919into a variety of combination studies.
Today's Conference Call and Webcast Reminder
The NewLink management team will host a conference call discussing the company's financial results and recent corporate developments on (
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. By leveraging its dual cancer immunotherapy platforms, NewLink has established itself as a leader in cancer immunotherapy. For more information please visit http://www.linkp.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: NewLink's financial guidance for 2013 and 2014; enrollment in its clinical trials for product candidates based on NewLink's HyperAcute and IDO platform technologies; its timing of release of clinical data from ongoing clinical studies; its plans related to moving additional indications into clinical development; NewLink's future financial performance, results of operations, cash position and sufficiency of capital resources to fund its operating requirements; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink's Quarterly Report on Form 10-Q for the period ended
|Condensed Consolidated Statements of Operations (unaudited)|
|(in thousands, except share and per share amounts)||Quarter Ended||Year Ended|
|Research and development||5,208||4,489||22,713||17,838|
|General and administrative||2,999||2,103||9,521||7,108|
|Loss from operations||(7,913||)||(6,293||)||(31,141||)||(23,259||)|
|Other income (expense), net||(3||)||(26||)||91||(62||)|
|Net loss before taxes||(7,916||)||(6,319||)||(31,050||)||(23,321||)|
|Income tax expense||(130||)||--||(130||)||--|
|Net loss per common share, basic and diluted||$||(0.31||)||$||(0.30||)||$||(1.23||)||$||(1.12||)|
|Weighted average number of common shares outstanding||25,890,638||20,929,184||25,275,179||20,779,450|
|Condensed Consolidated Balance Sheets (unaudited)|
|(In thousands, except share and per share data)||Year Ended|
|Cash, cash equivalents and certificates of deposit||$||61,540||$||21,744|
|Prepaid expenses, other receivables and other current assets||2,430||1,645|
|Total current assets||63,970||23,389|
|Property and equipment, net||6,587||6,040|
|Liabilities and Stockholders' Equity|
|Accounts payable and accrued expenses||$||3,473||$||2,631|
|Income tax payable and other current liabilities||319||204|
|Total current liabilities||3,876||2,919|
|Long term liabilities:|
|Obligations under capital leases||46||38|
|Deferred rent, excluding current portion||1,321||1,405|
|Total long term liabilities||8,354||8,583|
|Additional paid-in capital, net||194,038||122,514|
|Deficit accumulated during the development stage||(135,977||)||(104,797||)|
|Total Stockholders' equity||58,327||17,927|
|Total liabilities and Stockholders' equity||$||70,557||$||29,429|
Chief Financial Officer
News Provided by Acquire Media